榮昌生物-B(09995.HK)擬申請科創板上市
格隆匯5月10日丨榮昌生物-B(09995.HK)宣佈,公司建議向中國相關監管機構申請配發及發行不多於5442.6萬股A股,以及建議向上海證券交易所申請批准A股在科創板上市及買賣。
公司認為,在科創板上市將加速集團的發展,提高其競爭力,對公司及其股東整體有利,有利於加強公司的可持續發展。於公司H股於2020年11月上市後,A股發行使公司能夠成為一間雙重上市公司,進一步豐富其資本基礎及開發國內外融資平台。在中國國內上市亦將使公司能夠進一步提升其品牌形象及在國內市場的影響力。
全球發售的募集資金為公司核心產品以及產品線中其他主要產品的研發及商業化提供了有力的支持,A股發行的所得款項將使公司能夠推進針對中國各種適應症的候選藥物的臨牀試驗,並滿足候選藥物商業化生產所需的資金需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.